Evidence map›Paper›PMID 39665559›Full record

ArticleMicrobiology spectrum2025

Advancing poliovirus eradication: lessons learned from piloting direct molecular detection of polioviruses in high-risk and priority geographies.

Paula L Marcet, Brandon Short, Ashley Deas, Hong Sun, Chelsea Harrington, Shahzad Shaukat, Muhammad Masroor Alam, Marycelin Baba, Adedayo Faneye, Prossy Namuwulya and 13 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Paula L MarcetDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-0676-3020
Brandon ShortDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ashley DeasTanaq, Contracting agency to the Division of Viral Diseases, CDC, Atlanta, Georgia, USA.ORCID 0009-0005-3950-9423
Hong SunDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-1306-8050
Chelsea HarringtonDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-2879-444X
Shahzad ShaukatWorld Health Organization, Global Polio Laboratory Network Headquarters, Geneva, Switzerland.ORCID 0000-0003-3502-6940
Muhammad Masroor AlamNational Institute for Health, Islamabad, Pakistan.
Marycelin BabaNational Polio Laboratory, Maiduguri, Nigeria.
Adedayo FaneyeNational Polio Laboratory, Ibadan, Nigeria.
Prossy NamuwulyaUganda Virus Research Institute, Entebbe, Uganda.
Lea Necitas ApostolNational Polio Laboratory, Research Institute for Tropical Medicine, Manila, Philippines.
Tamer ElshaarawyPolio Regional Reference Laboratory, VACSERA, Greater Cairo, Egypt.
John Kofi OdoomNoguchi Memorial Institute for Medical Research, Accra, Ghana.
Peter BorusKenya Medical Research Institute, Nairobi, Kenya.
Shelina MoonsamyNational Institute of Communicable Diseases, Johannesburg, South Africa.
Yogolelo RizikiNational Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.
Marie Claire Endegue ZangaCentre Pasteur du Cameroun, Yaoundé, Cameroon.
Mesfin TeferaNational Polio Laboratory, Addis Ababa, Ethiopia.
Anfumbom K W KfutwahWorld Health Organization, Regional Office for Africa, Brazzaville, Democratic Republic of Congo.
Salmaan SharifWorld Health Organization, Regional Office for the Eastern Mediterranean, Amman, Jordan.ORCID 0000-0002-2558-3068
Varja GrabovacWorld Health Organization, Regional Office for the Western Pacific, Manila, Philippines.
Cara C BurnsDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-2582-2476
Nancy GerloffDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-5696-8318

Funding

World Health Organization 001
6 · The paper itself

Abstract

In the Global Polio Laboratory Network (GPLN), poliovirus (PV) screening results from acute flaccid paralysis (AFP) surveillance is based on virus isolation (VI) through cell culture, entailing long turnaround times and the amplification of live poliovirus. An alternative Direct Detection strategy (DD-ITD) for screening viral nucleic acid from stools, bypassing the need for virus culture, has been developed and extensively validated by GPLN partners. A multi-laboratory demonstration project was conceived to field-test the DD-ITD method by GPLN laboratories from the WHO African, Western Pacific, and Eastern Mediterranean regions, where wild serotype 1 or vaccine-derived polioviruses still circulate. Strategically selected laboratories were tasked to simultaneously process stool suspensions with the current gold-standard VI method and the new DD-ITD strategy. Results from 12 laboratories were compiled and analyzed to assess the quality of each RNA extraction and rRT-PCR run. Matched results for both methods of over 10,500 specimens showed an overall method agreement of 91%. All laboratories detected more PV presumptive positive samples with the DD-ITD strategy than with VI, but a large proportion of DD-ITD positive results (72%) were inconclusive or non-typeable, requiring confirmation through sequencing. A total of 298 (2.8%) samples were PV positive using both methods, 828 (7.9%) positive only for DD-ITD, and 62 (0.6%) positive only with VI. The DD-ITD overall performance, quality of results, and agreement between method results varied significantly across participating laboratories. DD-ITD implementation would entail building proficiency in advanced molecular laboratory techniques and data analysis, and increased demand for confirmatory sequencing. IMPORTANCE: Surveillance of acute flaccid paralysis (AFP) and sensitive poliovirus detection are key components of the WHO Global Polio Eradication Strategy. This work summarizes the results of a multi-laboratory evaluation designed to field-test the performance and applicability of a molecular Direct Detection strategy (DD-ITD) that does not require amplification of live poliovirus. AFP samples were processed in parallel with both the DD-ITD and the current gold-standard PV detection methodology, based on virus isolation (VI) through cell culture. All participating laboratories detected more PV presumptive positive samples using the DD-ITD strategy than with virus isolation methodology, although a higher proportion of DD-ITD results required confirmatory sequencing. Significant variability among laboratories was observed in the quality of the results and overall DD-ITD performance. Implementing DD-ITD would entail building proficiency in advanced molecular laboratory techniques and strengthening data analysis skills.

Indexed as

Disease EradicationPoliomyelitisPoliovirusFecesGlobal HealthHumansPilot ProjectsRNA, ViralRNA, Viralacute flaccid paralysisdirect detectionnucleic acid extractionpolioviruspoliovirus eradicationreal-time RT-PCRsurveillance

Identifiers

PMID39665559
PMCPMC11792523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.